Smith, Jaclyn A., Kitt, Michael M., Morice, Alyn, Birring, Surinder S., McGarvey, Lorcan P., Sher, Mandel R., Li, Yu Ping, Wu, Wen Chi, Xu, Zhi Jin, Muccino, David R., Ford, Anthony P., Hull, James, Carr, Warner W., Goldsobel, Alan B., Gross, Gary N., Holcomb, John R., Hussain, Iftikhar, Spangenthal, Selwyn, Storms, William, Elkayam, David, Steven, Gary C., Krainson, James, Fakih, Faisal Alfonso, Matz, Jonathan, Brooks, Gregory Daniel, Casale, Thomas, Berman, Gary D., Condemi, John J., Greos, Leon S., Gogate, Shaila U., Sher, Ellen R., Friesen, Jason H., Schenkel, Eric J., Bernstein, David Isaac, Corren, Jonathan, Sundar, Krishna, Gotfried, Mark H., Montanaro, Anthony, Lumry, William R., Amar, Niran J., Kaplan, Michael S., Prenner, Bruce M., Murphy, Thomas R., Good, James S., Parker, Sean, Harrison, Tim, Pavord, Ian, Brightling, Christopher, Djukanovic, Ratko, McQuaid, Douglas, Denenberg, Michael, Ettinger, Neil A., Iyer, Vivek, "Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial", The Lancet Respiratory Medicine, 2020